Hemofarm

Hemofarm a.d., formally Hemofarm a.d. Farmaceutsko-hemijska industrija Vršac, is a Serbian pharmaceutical manufacturer headquartered in Vršac. Established on 1 June 1960, the company developed from a domestic medicines producer into one of Serbia’s largest pharmaceutical businesses and a significant exporter from the country. Its principal activities are the manufacture and marketing of prescription and over-the-counter medicines, together with related pharmaceutical and medical products. The company’s portfolio is built around generic medicines. According to reference material describing the business, Hemofarm covers more than 140 International Nonproprietary Names and approximately 280 pharmaceutical forms and dosage forms. This breadth enables it to serve several therapeutic and consumer-health segments rather than depend on a single product franchise. Its activities include production for the Serbian market, exports to neighboring Southeast European countries, and manufacturing and development linked to the wider STADA network. Hemofarm expanded substantially during the 2000s. It established a medicine factory in Republika Srpska, Bosnia and Herzegovina, in 2003 and, during the same period, maintained a network of subsidiaries in Serbia and Montenegro. In 2004, it acquired four Serbian pharmaceutical companies, a move that materially increased its domestic market share. The company was acquired by German pharmaceutical group STADA for €480 million in 2006, and it has operated as part of the STADA Group since 9 August 2009 according to the cited company history. Research and development has been an important part of Hemofarm’s evolution. Its R&D division was created in 1990. STADA subsequently recognized the Vršac operation as a competence center for developing generic products for local and regional markets as well as for the broader group. From 2007, Hemofarm intensified development work aimed at products for registration and sale in the European Union, linking its Serbian manufacturing base with more demanding international regulatory and commercial requirements. Hemofarm also continued to consolidate its domestic position after joining STADA. In August 2016, it acquired the assets of the smaller Serbian pharmaceutical company Ivančić i sinovi; the transaction value was not publicly specified in the supplied reference material. The company is described as operating in more than 30 countries on three continents and employing approximately 3,000 people. Its current identity is therefore that of a regional generic-pharmaceutical platform: locally rooted in Serbia, integrated into a German-owned international group, and focused on scalable medicines production, regulatory development, exports, and access to established pharmaceutical treatments.

Hemofarm was established in Vršac on 1 June 1960. Its initial and enduring role was as a Serbian producer of medicines, serving the domestic market while gradually building the industrial capabilities needed for a wider regional presence. The company’s later development was shaped by the expansion of generic pharmaceuticals, in which manufacturing scale, regulatory expertise, and the ability to supply multiple dosage forms are central competitive factors. A dedicated research and development division was established in 1990. This gave Hemofarm an internal platform for developing and adapting medicines rather than limiting the company to contract manufacturing or the sale of externally developed products. R&D became increasingly important after the company’s international expansion, particularly as it sought to prepare products for registration in markets with more demanding regulatory requirements. In 2003, Hemofarm opened its first medicine factory in Republika Srpska, Bosnia and Herzegovina. At that point, the business had expanded into a group structure comprising 21 subsidiaries, including 12 in Serbia and the remainder in Montenegro, according to the cited historical account. The move illustrated Hemofarm’s strategy of extending its manufacturing and commercial footprint beyond its Vršac base while retaining a strong position in the former Yugoslav pharmaceutical markets. The company pursued further consolidation in Serbia in 2004, acquiring four other Serbian pharmaceutical companies. The acquisitions reportedly increased Hemofarm’s domestic market share from 15% to 45%. A later reference states that the company held a 30.7% share of the Serbian market measured by production and imports in 2011. These figures indicate the scale Hemofarm achieved before and after its integration into a multinational group, although the measures and periods are not directly comparable. STADA Arzneimittel acquired Hemofarm in 2006 for a reported €480 million. The transaction connected a major Serbian medicines producer with a German pharmaceutical group specializing in established and generic products. The supplied company history identifies 9 August 2009 as the date on which Hemofarm became a member of the German STADA Group. Under that ownership, the Vršac organization continued to function as a significant manufacturing and development base within a broader international network. Hemofarm’s R&D role expanded during this period. STADA recognized the company as a competence center for the development of new generic products for Serbian and regional markets and for the STADA Group as a whole. Intensive development of products intended for registration and sale in the European Union began in 2007, reflecting an effort to align local technical capabilities with EU regulatory standards and export opportunities. The company continued its Serbian portfolio expansion in August 2016 by acquiring the assets of Ivančić i sinovi, a smaller pharmaceutical company. No purchase price is provided in the supplied sources. Hemofarm is described as active in more than 30 countries on three continents and as employing around 3,000 people. Its historical trajectory is consequently defined by four linked developments: the creation of a Serbian manufacturing base, regional expansion, consolidation of the domestic pharmaceutical sector, and integration into the STADA Group as an international generic-medicines platform.

• 2016

  Ivančić i sinovi asset acquisition

  [1]Hemofarmen.wikipedia.org

  Hemofarm acquired the assets of Serbian pharmaceutical company Ivančić i sinovi.

• 2009

  Joined the STADA Group

  [1]Hemofarmen.wikipedia.org

  Hemofarm became a member of the German STADA Group on 9 August 2009, according to the cited company history.

• 2007

  EU-oriented product development intensified

  [1]Hemofarmen.wikipedia.org

  Hemofarm intensified development of products intended for registration and sale in European Union markets.

• 2006

  Acquired by STADA

  [1]Hemofarmen.wikipedia.org

  STADA Arzneimittel acquired Hemofarm for a reported €480 million.

• 2004

  Acquisition of four Serbian pharmaceutical companies

  [1]Hemofarmen.wikipedia.org

  Hemofarm acquired four Serbian pharmaceutical companies, with the transaction reportedly raising its domestic market share from 15% to 45%.

• 2003

  Expansion into Republika Srpska

  [1]Hemofarmen.wikipedia.org

  The company opened its first medicine factory in Republika Srpska, Bosnia and Herzegovina, and operated through a network of subsidiaries in Serbia and Montenegro.

• 1990

  Research and development division established

  [1]Hemofarmen.wikipedia.org

  Hemofarm created an R&D division, laying the foundation for in-house generic-product development.

• 1960

  Hemofarm established in Vršac

  [1]Hemofarmen.wikipedia.org

  Hemofarm was established on 1 June 1960 in Vršac, Serbia.

A broad-based Serbian generic-pharmaceutical manufacturer combining domestic market strength, export production, and R&D capabilities within the international STADA Group.

• Generic pharmaceuticals

  Prescription generic medicines

  Prescription medicines form a core part of Hemofarm’s manufacturing and commercial portfolio. The company develops and produces medicines identified by International Nonproprietary Names, supplying established active ingredients in multiple finished forms. Its R&D organization supports product development for Serbia, Southeast Europe, and the wider STADA Group, including products intended for European Union registration.

• Consumer health

  Over-the-counter medicines

  Hemofarm manufactures and markets over-the-counter medicines alongside its prescription portfolio. These products are intended for non-prescription use and contribute to the company’s broad domestic and regional offering. Specific brands and therapeutic categories are not identified in the supplied reference material.

• Medical products

  Medical and pharmaceutical products

  In addition to medicines, Hemofarm is described as manufacturing and marketing related pharmaceutical and medical products. The supplied sources do not provide a sufficiently detailed product-by-product listing, but the category reflects the company’s broader healthcare manufacturing scope.

• 2016

  Acquire Ivančić i sinovi assetsM&A

  Background

  Hemofarm continued consolidating and expanding its Serbian pharmaceutical activities after joining the STADA Group.

  Action taken

  The company acquired the assets of the smaller Serbian pharmaceutical company Ivančić i sinovi.

  Aftermath

  The acquisition expanded Hemofarm’s domestic asset base; the supplied sources do not state the purchase price or detailed operational consequences.

  Source

• 2006

  Accept STADA acquisitionM&A

  Background

  Hemofarm had become a major Serbian and regional pharmaceutical producer through manufacturing expansion and domestic acquisitions.

  Action taken

  STADA Arzneimittel acquired Hemofarm in a transaction reported at €480 million.

  Aftermath

  The acquisition placed Hemofarm within a German international pharmaceutical group and supported its subsequent role as a STADA development and manufacturing competence center.

  Reported acquisition value. €480 million transaction value (2006)

  Source

1. 1Hemofarmen.wikipedia.org
2. 2Hemofarm official websitehemofarm.com